Skip to main content

20th International Myeloma Workshop Main banner

Myeloma Microenvironment and immune profiling

Myeloma Microenvironment and immune profiling

Type here to filter the list

P-377: CD38 targeting in Multiple Myeloma
P-378: Longitudinal antibody and T-cell kinetics over four doses of COVID-19 vaccination and predictors of poor response in patients with multiple myeloma.
P-379: Variable humoral and cellular responses to SARS-CoV-2 Bivalent booster vaccination in patients with Multiple Myeloma
P-380: Immunological Aging Is Associated with Worse Clinical Outcome in Elderly Newly Diagnosed Multiple Myeloma Patients
P-381: Mezigdomide (CC-92480) activates innate and adaptive immune populations in the bone marrow microenvironment of heavily pre-treated multiple myeloma patients
P-382: Dysregulations of the immune tumor microenvironment in multiple myeloma
P-383: A 16-gene signature reflecting tumor microenvironment predicts the risk of multiple myeloma patients treated by bortezomib-based therapies
P-384: EXPLOITING FIBER-RICH DIET TO PERTURB THE MICROBIOTA-IMMUNE AXIS AND THWART MULTIPLE MYELOMA PROGRESSION
P-385: Single cell RNA sequencing reveals activated translation machinery in memory T cells among exceptional responders to lenalidomide
P-386: A high risk of progression from smoldering to symptomatic multiple myeloma was predicted by bone marrow and circulating gamma delta T cells.
P-387: Bone marrow immune composition reflects multiple myeloma evolution and influences patients’ outcome
P-388: An IL-1β driven neutrophil-stromal cell axis fosters a BAFF-rich tumor-supportive bone marrow environment in multiple myeloma patients
P-389: Progression to Myeloma reflects accelerating immunosenescence, loss of tumour MHC class I, and tumour growth-associated inflammation
P-390: The differentiation and expansion of T cell clonotypes in the bone marrow following ASCT: insights from the Phase 2 CARDAMON study
P-391: Checkpoint inhibitor PD-1H/VISTA mediates its effects on osteoclast cytoskeleton in myeloma bone disease via c-Src/Rac1 signaling
P-392: Daratumumab-induced in vivo immune modulation in relapsed and/refractory multiple myeloma patients treated with Daratumumab-Len-Dex
P-393: COVID-19 vaccine acceptance/hesitancy and influence on infection in patients with multiple myeloma: A national-wide multicenter survey in China
P-394: Proteomic Analysis to Discover Bone Marrow Plasma Biomarkers Predicting Outcome Following Autologous Stem Cell Transplantation in Multiple Myeloma Patients
P-395: THE GUT MICROBIOTA CHANGES DURİNG MULTIPLE MYELOMA TREATMENT
P-396: Investigation of T-cell fitness and mechanisms of drug resistance in selinexor treated patients with relapsed/refractory multiple myeloma
P-397: Polyclonal immunoglobulin recovery in myeloma patients receiving maintenance after autologous hematopoietic stem cell transplantation with carfilzomib, lenalidomide and dexamethasone or lenalidomide.
P-398: Dynamic immune response in multiple myeloma patients infected with SARS-CoV-2 Omicron BA.4/5 subvariant in China
P-399: Isatuximab Promotes Immune Activation in the Bone Marrow Microenvironment of Patients with High Risk Smoldering Multiple Myeloma
P-400: An immune atlas of the dysfunctional cellular and antibody response to COVID-19 vaccination in patients with multiple myeloma
P-401: miRNA-seq and clinical validation of miR-221/222 cluster in multiple myeloma
P-402: Inhibition of proline production by stromal cells negatively impacts myeloma tumor growth by reducing cytokine and growth factor secretion.
P-403: Identification and quantification of novel circular RNAs (circRNAs) deriving from the apoptosis-related BCL2L12 gene in multiple myeloma cells, using targeted nanopore sequencing and nested qPCR
P-404: Single-Cell Profiling Reveals Inflammaging-Associated Dysregulations in Rapidly Progressing Multiple Myeloma Patients
P-405: ISOTYPE MATCHED IMMUNOPARESIS COULD HELP IN PREDICTING PROGRESSION TO MULTIPLE MYELOMA IN MGUS PATIENTS
P-406: Development of a 3D bioreactor model using a perfusion bioreactor to study osteocyte progenitor cells and the Involvement of single ECM molecules in Multiple Myeloma Bone Disease
P-407: 3D organoid model: Using primary cells to study therapeutic effects on patients’ myeloma tumor niche
P-408: Differential peripheral cytokine profile and tumor microenvironment in patients with or without a history of BCMA-directed therapy prior to elranatamab: Analysis of MagnetisMM-3
P-409: Elevated LAG-3 expression in plasma cells and lymphoid subpopulations at distinct stages of Multiple Myeloma disease progression
P-411: Large-scale single-cell dissection of immune dysregulation in patients with monoclonal gammopathies
P-412: Loss of 3’U-tRFHisGTG in predicting poor survival and treatment outcome in multiple myeloma
P-413: Inflammatory markers characterize neutrophils and C1q+ TAMs in the day 100 bone marrow aspirate post ASCT of patients with early progression
P-414: Single-Cell Profiling Reveals Aggressive Tumor Subcluster and Compromised Immune State in Multiple Myeloma
P-415: Profiling of patient bone marrow adipocytes in the myeloma microenvironment
P-416: Immunophenotypic profile defines cytogenetic stability and unveils distinct prognoses in patients with newly-diagnosed multiple myeloma (NDMM)
P-417: SKY92 gene expression profiling and cytogenetics according to R2-ISS for multiple myeloma risk classification
P-418: The metabolic profile of multiple myeloma
P-491: Ratio of NK cells expressingNKG2A or not (NKG2A+pos/NKG2A-neg) is associated with post-transplant remission period for myeloma patients who have received autologous transplantation
P-497: Longitudinal single-cell multi-omic profiling of human T cells in newly diagnosed multiple myeloma patients over the course of VRd and autologous stem cell transplant therapy
P-498: Lenalidomide and Pomalidomide Experience: Thrombotic Risk in Hematological Neoplasms